Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

CAR-T Digest - August 2020

22 December 2025: Simcere Zaiming builds exclusive partnership with Ipsen for Simcere Zaiming’s innovative antibody drug conjugate

Simcere Zaiming and Ipsen entered an exclusive licensing partnership granting Ipsen global rights outside Greater China to develop, manufacture, and commercialize SIM0613, an antibody-drug conjugate (ADC)
Under the agreement, Simcere Zaiming is eligible to receive up to $1.06 billion in total consideration, including upfront payments, development, regulatory and commercial milestones, along with tiered royalties subject to successful development and approvals
SIM0613 targets the LRRC15 protein and is positioned as a potential best-in-class ADC for solid tumors with high unmet medical needs, supported by robust preclinical efficacy data
The ADC is designed for superior tumor penetration and differentiated anti-tumor activity, leveraging Simcere Zaiming’s proprietary ADC platform
The program is expected to enter Phase 1 clinical development in the second half of 2026